Dr. Mirza on Niraparib Efficacy Across Ovarian Cancer Subgroups OncLive 1:30 7 years ago 219 Далее Скачать
Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer OncLive 2:18 5 years ago 296 Далее Скачать
Dr. Mirza Discusses Niraparib Dose Modifications for Ovarian Cancer Patients With Low Body Weight OncLive 2:26 6 years ago 374 Далее Скачать
Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian Cancer OncLive 0:52 4 years ago 110 Далее Скачать
Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer OncLive 1:41 7 years ago 307 Далее Скачать
Dr. Mirza on the Impact of PARP Inhibitors in Ovarian Cancer OncLive 0:53 6 years ago 56 Далее Скачать
Dr. Mirza on the Evolving Treatment Landscape in Recurrent Ovarian Cancer OncLive 1:30 4 years ago 167 Далее Скачать
Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer OncLive 2:18 4 years ago 100 Далее Скачать
ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer OncLive 8:29 4 years ago 626 Далее Скачать
Niraparib significantly improves outcomes for ovarian cancer patients ecancer 3:23 7 years ago 612 Далее Скачать
Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian Cancer OncLive 2:11 5 years ago 195 Далее Скачать
Niraparib Shows Positive Data, Requires Different Dosing in Ovarian Cancer Targeted Oncology 1:50 4 years ago 490 Далее Скачать
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer VJOncology 9:25 7 years ago 1 171 Далее Скачать
Combination therapy to treat ovarian cancer: promising results from the ANANOVA trial VJOncology 2:17 6 years ago 71 Далее Скачать
